Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Revenues
Total revenues	$ 752,750	$ 546,600	$ 1,449,394	$ 1,048,431
Cost and expenses
Research and development	228,071	146,427	438,773	275,504
Selling, general and administrative	327,203	310,549	655,142	577,414
Amortization of acquired intangible assets	5,700	0	11,400	0
Total cost and expenses	828,542	656,972	1,618,703	1,237,978
Loss from operations	(75,792)	(110,372)	(169,309)	(189,547)
Interest expense	(890)	(1,029)	(1,782)	(2,034)
Interest and other income, net	9,452	10,738	19,053	24,155
Loss before income taxes	(67,230)	(100,663)	(152,038)	(167,426)
Income tax benefit (expense)	261	(275)	(22)	(448)
Net loss	(66,969)	(100,938)	(152,060)	(167,874)
Unrealized gain (loss) on available-for-sale securities, net of tax and foreign currency translation adjustment	94	(90)	150	57
Comprehensive loss	$ (66,875)	$ (101,028)	$ (151,910)	$ (167,817)
Net loss per share (Note 14):
Basic (in dollars per share)	$ (0.47)	$ (0.74)	$ (1.07)	$ (1.24)
Diluted (in dollars per share)	$ (0.47)	$ (0.74)	$ (1.07)	$ (1.24)
Weighted-average number of shares used in computing basic and diluted net loss per share:
Basic (in shares)	143,279	136,388	142,395	135,632
Diluted (in shares)	143,279	136,388	142,395	135,632
Foresight Diagnostics, Inc.
Cost and expenses
Amortization of acquired intangible assets	$ 5,707	$ 0	$ 11,416	$ 0
Product revenues
Revenues
Total revenues	747,929	544,427	1,441,796	1,044,463
Cost and expenses
Cost of revenues	266,597	199,531	511,800	384,143
Licensing and other revenues
Revenues
Total revenues	4,821	2,173	7,598	3,968
Cost and expenses
Cost of revenues	$ 964	$ 465	$ 1,572	$ 917